Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial

by rss feed | Nov 9, 2026 | News Feeds

Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum), a clinical-stage biopharmaceutical company pioneering differentiated small...

Better reimbursement programs can improve access to cancer clinical trials

by rss feed | Nov 9, 2026 | News Feeds

New research reveals that participating in cancer clinical trials can cause financial burdens that are shaped by both socioeconomic and logistical factors. Read Original...

Modified zinc finger protein reduces brain plaques in Alzheimer’s mice

by rss feed | Nov 9, 2026 | News Feeds

A KAIST-led research team has found that a protein involved in gene regulation can suppress the harmful aggregation of amyloid-beta, a peptide associated with Alzheimer's disease. Read Original...

Combat Medical reports 68% high-grade recurrence-free survival at 12 months in BCG-unresponsive non-muscle invasive bladder cancer study

by rss feed | Nov 9, 2026 | News Feeds

Combat Medical (Combat), a medical device company optimizing the delivery and efficacy of cancer therapeutics, today announced new real-world data showing 68% high-grade recurrence-free survival (HG-RFS) at 12 months in patients with Bacillus Calmette-Guérin...

Study links everyday nanoplastics to severe lung inflammation risk

by rss feed | Nov 9, 2026 | News Feeds

Everyday plastic products, including water bottles, disposable cups, and packaging, can break down over time into tiny fragments known as nanoplastics. Read Original...